Traders Purchase High Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the target of unusually large options trading on Tuesday. Stock investors purchased 4,480 call options on the company. This is an increase of 124% compared to the average daily volume of 1,996 call options.

Analyst Ratings Changes

MIST has been the topic of several recent analyst reports. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 1st. Wells Fargo & Company lifted their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, HC Wainwright upped their price objective on shares of Milestone Pharmaceuticals from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Milestone Pharmaceuticals Price Performance

NASDAQ:MIST traded down $0.07 during trading hours on Tuesday, hitting $2.29. The stock had a trading volume of 7,531,372 shares, compared to its average volume of 2,254,538. The firm has a market capitalization of $194.61 million, a price-to-earnings ratio of -2.79 and a beta of 0.41. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24. The company has a 50 day simple moving average of $2.18 and a two-hundred day simple moving average of $1.92. Milestone Pharmaceuticals has a one year low of $0.63 and a one year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. Research analysts forecast that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MIST. Propel Bio Management LLC purchased a new position in shares of Milestone Pharmaceuticals in the first quarter worth $1,161,000. Walleye Capital LLC bought a new position in Milestone Pharmaceuticals in the first quarter worth $74,000. Simplify Asset Management Inc. increased its stake in shares of Milestone Pharmaceuticals by 16.5% in the 2nd quarter. Simplify Asset Management Inc. now owns 990,000 shares of the company’s stock worth $1,921,000 after acquiring an additional 140,000 shares in the last quarter. Valeo Financial Advisors LLC boosted its position in shares of Milestone Pharmaceuticals by 553.5% in the 2nd quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock worth $254,000 after purchasing an additional 110,699 shares in the last quarter. Finally, Bay Rivers Group bought a new position in shares of Milestone Pharmaceuticals during the second quarter valued at $28,000. 86.18% of the stock is owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.